| Literature DB >> 35570997 |
Satoru Kudose1, Geetha Jagannathan1, Dominick Santoriello1, Miroslav Sekulic1, Ibrahim Batal1, M Barry Stokes1, Vivette D D'Agati1, Glen S Markowitz1.
Abstract
Entities:
Keywords: heavy/light chain immunofluorescence; kidney biopsy; monoclonal gammopathy of renal significance
Year: 2022 PMID: 35570997 PMCID: PMC9091611 DOI: 10.1016/j.ekir.2022.01.1071
Source DB: PubMed Journal: Kidney Int Rep ISSN: 2468-0249
Figure 1A general workflow for evaluation of kidney disease with monotypic staining by conventional IF. In individual cases, clinical history, pathologic findings, and availability of ancillary tests must be carefully considered. IF, immunofluorescence.
HLC-IF on independent samples of glomerular diseases with monotypic or bitypic deposits; comparison of results at Columbia University and Mayo Clinic
| Pathology | CUIMC | Mayo | ||
|---|---|---|---|---|
| Monotypic deposits by conventional IF | Number of cases polytypic by HLC-IF | Monotypic deposits by conventional IF | Number of cases polytypic by HLC-IF | |
| PGNMID | IgG1κ | 2/5 | ||
| IgG1λ | 0/1 | |||
| IgG2κ | 0/1 | |||
| IgG3κ | 0/12 | IgG3κ | 2/7 | |
| IgG3λ | 0/1 | IgG3λ | 0/3 | |
| Immunotactoid GN | IgG1κ | 2/2 | ||
| IgG1λ | 0/3 | |||
| IgG1κ and IgG2κ | 1/1 | |||
| IgG2κ | 2/2 | |||
| Monotypic or bitypic MN | IgG1κ | 1/3 | ||
| IgG3λ | 0/1 | |||
| IgG1κ and IgG3κ | 2/2 | IgG3κ | 0/1 | |
| Monotypic fibrillary GN | IgG1κ | 2/3 | IgGλ | 3/6 |
| Monotypic or bitypic anti-GBM disease | IgG1κ | 2/2 | IgGκ | 0/1 |
| IgG1λ | 0/3 | IgGλ | 0/2 | |
| IgG1λ and IgG4λ | 1/1 | |||
| IgMκ | 0/1 | |||
| IgAλ | 1/2 | |||
| 1/6 | ||||
| LC-restricted IgA nephropathy/vasculitis | IgAκ | 0/8 | ||
| IgAλ | 3/14 | IgAλ | 6/12 | |
CUIMC, Columbia University Irving Medical Center; GBM, glomerular basement membrane; GN, glomerulonephritis; HLC, heavy and light chain; IF, immunofluorescence; LC, light chain; MN, membranous nephropathy; PGNMID, proliferative glomerulonephritis with monoclonal immunoglobulin deposits.
These cases were stained with IgAκ and IgAλ HLC-IF.